Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biogen Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.biogen.com
Year Founded: 1978
Status: Public
Industry Sector: HealthTechnology
CEO: Christopher A. Viehbacher, CPA
Number Of Employees: 7,605
Enterprise Value: $26,652,728,000
PE Ratio: 11.69
Exchange/Ticker 1: NASDAQ:BIIB
Exchange/Ticker 2: N/A
Latest Market Cap: $19,221,964,800
BioCentury | Apr 3, 2025
Product Development
Amid Alzheon Alzheimer’s setback, PIs see new surrogate endpoint
But study’s PIs argue for hippocampal volume as a new surrogate endpoint
BioCentury | Apr 1, 2025
Distillery Therapeutics
Conditional NRF2 activator for oxidative stress disorders
BioCentury | Mar 29, 2025
Data Byte
EMA’s CHMP snubs donanemab, even for APOE4 non-carriers
Lilly to seek re-examination. Also in March meeting, CHMP backs label expansions for Opdivo, Tevimbra and more
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Mar 19, 2025
Management Tracks
CFO Brian Stephenson exits Bridgebio
Plus: CEO Edward Kayne steps down at Stoke, and updates from Collegium, Pyxis, Recursion and Tonix
BioCentury | Mar 17, 2025
Product Development
Lundbeck’s next chapter: from psychiatry to rare neuro
Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Mar 7, 2025
Data Byte
MS market dynamics: Ocrevus still king as Kesimpta sales boom
Plus: Briumvi shows signs of growth, while sales of oral therapies remain mostly flat
BioCentury | Mar 6, 2025
Management Tracks
John King named commercial head at Dianthus
Plus: CMO Laura Gault steps down at Sage, and updates from Orbis and Nature’s Toolbox
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
Items per page:
1 - 10 of 2106